GlassScriptPhysician profile
Ava A Boswell
NPI 1679969497
$751.00
in general payments reported to CMS, 2019-2025
11 companies · $88.45 in 2025
The $88.45 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $142 · 2023: $240 · 2024: $280 · 2025: $88.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.14 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $152.92 | 2023-2024 | Vraylar |
| Neurocrine Biosciences, INC. | $138.25 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $112.26 | 2022-2024 | Invega Sustenna |
| Alkermes, INC. | $66.17 | 2022-2024 | Aristada, Lybalvi |
| Biogen, INC. | $64.34 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.30 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $51.61 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $42.55 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.01 | 2024-2025 | |
| Lundbeck LLC | $18.21 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $13.38 | 2023 | Austedo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ava Boswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.